Latest filing published 08 Feb 2022 for DiaMedica Therapeutics Inc., €43k.
Filing timeline
BuySaleInsider track record
Harry Alcorn: trading record in brief
Harry Alcorn discloses dealings in DiaMedica Therapeutics Inc. to SEC (Form 4). In total, 4 filings cover trades dated from 11 December 2018 to 15 September 2021.
Every open-market trade on record is a purchase: 3 purchases worth €95k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. So far in 2022, the count stands at 2 purchases and no sales.
The median purchase comes to €38k. The 3 purchases reviewed show no overlap with other insiders buying the same stock within a month.
The latest filing, published on 8 February 2022, reports an open-market purchase of €43k in DiaMedica Therapeutics Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Harry Alcorn
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 20,721 shares@ CA$3.09245.8% of flowCommon SharesTSXSEDI:3882435Canonical exit: 14 Nov 2021 (T+90)
- 15,000 shares@ CA$3.797340.4% of flowCommon SharesTSXSEDI:3882436Canonical exit: 14 Dec 2021 (T+90)
- 7,260 shares@ CA$2.6674100.0% of flowCommon SharesTSXSEDI:3412337Canonical exit: 14 Nov 2019 (T+90)
- 1,000 sharesCommon SharesTSXSEDI:3278735
4 of 4 declarations